1-butyl-3-[[2-furanyl(oxo)methyl]amino]thiourea is a complex organic molecule, and its specific importance in research likely depends on the context of its application. Without additional information about its specific use, it's difficult to give a detailed answer.
However, we can break down its structure and potential applications:
* **Structure:** The name itself provides a clue to its structure. It's a thiourea derivative, meaning it contains the thiourea functional group (-NH-C(=S)-NH-). The molecule has a butyl group (C4H9-) attached to one nitrogen of the thiourea, and a furanyl(oxo)methyl group attached to the other nitrogen. This furanyl(oxo)methyl group (C4H3O-CO-CH2-) is derived from furan, a five-membered ring containing oxygen, with a carbonyl group (C=O) and a methyl group (CH3) attached.
* **Potential Applications:**
* **Pharmacology:** Thiourea derivatives are known to exhibit various biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The specific structure of this compound could potentially make it an interesting candidate for drug development.
* **Materials Science:** Thioureas are often used as building blocks for supramolecular assemblies and organic materials due to their ability to form strong hydrogen bonds. The presence of the furanyl(oxo)methyl group might introduce interesting electronic and optical properties to the material.
* **Analytical Chemistry:** The compound might be useful as a reagent for the detection and quantification of certain analytes, potentially due to its selective interactions with specific molecules.
**To get a more precise answer about the importance of 1-butyl-3-[[2-furanyl(oxo)methyl]amino]thiourea in research, you need to provide more context:**
* **What field is it being used in?** (e.g., organic synthesis, drug discovery, materials science)
* **What is its specific purpose in that field?** (e.g., a new drug candidate, a building block for a new material, a reagent for an analytical method)
Providing this additional information will enable me to give you a more detailed and relevant explanation.
ID Source | ID |
---|---|
PubMed CID | 4071290 |
CHEMBL ID | 1499858 |
CHEBI ID | 120622 |
Synonym |
---|
MLS000550566 , |
smr000115003 |
n-butyl-2-(2-furoyl)hydrazinecarbothioamide |
STK449408 |
n-butyl-2-(furan-2-ylcarbonyl)hydrazinecarbothioamide |
CHEBI:120622 |
1-butyl-3-(furan-2-carbonylamino)thiourea |
AKOS003293852 |
HMS2404A15 |
CHEMBL1499858 |
1-butyl-3-[[2-furanyl(oxo)methyl]amino]thiourea |
Q27208752 |
Class | Description |
---|---|
furoic acid | A monocarboxylic acid that consists of a furan ring having a single carboxylic acid group on any ring position and derivatives thereof. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.6310 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 50.1187 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 24.0353 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |